These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25390549)

  • 1. The core mechanism of dry eye disease is inflammation.
    Wei Y; Asbell PA
    Eye Contact Lens; 2014 Jul; 40(4):248-56. PubMed ID: 25390549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease.
    Reyes JL; Vannan DT; Eksteen B; Avelar IJ; Rodríguez T; González MI; Mendoza AV
    Mediators Inflamm; 2018; 2018():2532314. PubMed ID: 30158831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
    Baudouin C; Irkeç M; Messmer EM; Benítez-Del-Castillo JM; Bonini S; Figueiredo FC; Geerling G; Labetoulle M; Lemp M; Rolando M; Van Setten G; Aragona P;
    Acta Ophthalmol; 2018 Mar; 96(2):111-119. PubMed ID: 28390092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular evidence for the role of inflammation in dry eye disease.
    Ganesalingam K; Ismail S; Sherwin T; Craig JP
    Clin Exp Optom; 2019 Sep; 102(5):446-454. PubMed ID: 30630216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Inflammatories in the Treatment of Dry Eye Disease: A Review.
    Perez VL; Mah FS; Willcox M; Pflugfelder S
    J Ocul Pharmacol Ther; 2023 Mar; 39(2):89-101. PubMed ID: 36796014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage.
    Xia Y; Zhang Y; Du Y; Wang Z; Cheng L; Du Z
    J Nanobiotechnology; 2024 May; 22(1):233. PubMed ID: 38725011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease.
    Na KS; Mok JW; Kim JY; Rho CR; Joo CK
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5443-50. PubMed ID: 22789923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Dry Eye Disease.
    Marshall LL; Roach JM
    Consult Pharm; 2016 Feb; 31(2):96-106. PubMed ID: 26842687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in Dry Eye Disease: How Do We Break the Cycle?
    Rhee MK; Mah FS
    Ophthalmology; 2017 Nov; 124(11S):S14-S19. PubMed ID: 29055357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry Eye Disease and Tear Cytokine Levels-A Meta-Analysis.
    Roda M; Corazza I; Bacchi Reggiani ML; Pellegrini M; Taroni L; Giannaccare G; Versura P
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proinflammatory Markers, Chemokines, and Enkephalin in Patients Suffering from Dry Eye Disease.
    Nicolle P; Liang H; Reboussin E; Rabut G; Warcoin E; Brignole-Baudouin F; Melik-Parsadaniantz S; Baudouin C; Labbe A; Reaux-Le Goazigo A
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29673232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Oxidative and Anti-Inflammatory Micelles: Break the Dry Eye Vicious Cycle.
    Li S; Lu Z; Huang Y; Wang Y; Jin Q; Shentu X; Ye J; Ji J; Yao K; Han H
    Adv Sci (Weinh); 2022 Jun; 9(17):e2200435. PubMed ID: 35435328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot Topics in Dry Eye Disease.
    Chiaradia PA; Zeman Bardeci LA; Dankert S; Mendaro MO; Grzybowski A
    Curr Pharm Des; 2017; 23(4):608-623. PubMed ID: 27928967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of dry eye: Their strengths and limitations for studying human dry eye disease.
    Chang YA; Wu YY; Lin CT; Kawasumi M; Wu CH; Kao SY; Yang YP; Hsu CC; Hung KF; Sun YC
    J Chin Med Assoc; 2021 May; 84(5):459-464. PubMed ID: 33871392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.
    Barabino S; Chen Y; Chauhan S; Dana R
    Prog Retin Eye Res; 2012 May; 31(3):271-85. PubMed ID: 22426080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cluster Analysis of Dry Eye Disease Models Based on Immune Cell Parameters - New Insight Into Therapeutic Perspective.
    Lio CT; Dhanda SK; Bose T
    Front Immunol; 2020; 11():1930. PubMed ID: 33133058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research.
    Roy NS; Wei Y; Kuklinski E; Asbell PA
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO1-BIO19. PubMed ID: 28475698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.